No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

Book Review

“…The reported positivity rate in relation to tumor grade and histologic subtype is extremely variable, much like the reported overall positivity rate in breast carcinoma in general (1,2). Other studies have reported results similar to ours, but some have not (25)(26)(27)(28)(29)(30). These variations are, in part, probably related to inconsistencies in categorizing and grading breast carcinomas and to the fact that some studies that have small numbers and selected populations of breast carcinoma patients.…”

Study of pretreatment serum levels of HER‐2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

“…Studies conducted in patients with advanced breast carcinoma who received chemotherapy reached similar conclusions. Although results concerning the correlation between HER-2/neu tissue overexpression and chemoresistance have been contradictory, [43][44][45] all studies in which response to chemotherapy was assessed as a function of circulating HER-2/neu protein levels have produced negative results. 46,47 Further prospective studies that include greater numbers of patients with NSCLC who are treated with more homogeneous chemotherapy regimens would be useful to confirm this negative observation.…”

Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update

“…However, a missense mutation of p53 results in protein stabilization and accumulation in the nucleus. 65 Expression of p53 has been shown to be associated with poor outcome for patients with IBC in some studies, but has not been shown in others, [66][67][68] particularly when it is in combination with other markers, such as bcl-2 69 or HER2. 70 The different antibodies used in studies seem to produce different results as well.…”